Bracco announces long term strategic partnership with ulrich medical The partnership will bring a Bracco branded state of the art MR injector to the United States under an exclusive private label arrangement.

The EC granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union Vueway®, a new macrocyclic gadolinium-based contrast agent for CE-MRI, received Marketing Authorisation in the European Union By European Commission.

博莱科持续创新：拥抱精准医疗时代 探索博莱科参与 ECR 2024 欧洲放射学大会的活动行程表（2024年2月28日-3月3日），与全球优秀的医学专家们一起探讨CT造影剂优化，以及诊断成像的未来。

博莱科如何在 2023 年达到新的高度 MRI、可持续性和教育的创新 Bracco Diagnostics Inc. 销售和营销高级副总裁 Cosimo De Pinto 在RSNA 2023北美放射学会后接受采访，盛赞VUEWAY™造影剂、AI医疗成像创新和支持教育使博莱科达到新高度。

Samsung Medison and Bracco Imaging announce a new agreement Samsung Medison and Bracco Imaging endorsed a Memorandum of Understanding agreement to pioneer a new area for diagnostic ultrasound device and contrast agent at European Congress of Radiology 2024 held in Vienna, Austria on February 28th to March 3rd.

博莱科赋予教育什么价值？ 在ECR2024会议上，与Bracco Imaging全球营销战略和运营总监Francesca Pelliconi对话，她分享了博莱科对于教育的投入和承诺，将继续培养和优先考虑教育和知识共享的传统。

The Bracco Group announces the newly-created Bracco Japan The Bracco Group announces its direct presence in the Japanese market, where it has been doing business since 1990 through a successful joint venture with Eisai

创新对于博莱科的意义 在ECR2024学会上，Bracco Imaging全球研发主管Fabio Tedoldi与欧洲诊断成像公司（DIE）的Mélisande Rouger进行了一次关于创新的对话，并分享了创新对于博莱科的意义。 

Bracco Suisse and Verasonics: a new strategic partnership The collaboration focuses on combining Verasonics' Vantage®️ NXT Research Ultrasound Systems with Bracco's contrast agents to explore improved imaging performance in various research applications.

Blue Earth Diagnostics appoints Marco Campione as Chief Executive Officer Mr. Campione brings more than 25 years global experience in successful development and commercialization of diagnostic imaging agents and radiopharmaceuticals.